Archives of Pediatric Infectious Diseases

Published by: Kowsar

The Synergic Activity of Eucalyptus Leaf Oil and Silver Nanoparticles Against Some Pathogenic Bacteria

Maryam Asghar Heydari 1 , Masoud Mobini 1 and Mohammad Salehi 2 , 3 , *
Authors Information
1 MS.c, Young Researchers and Elites Club, Tonekabon Branch, Islamic Azad University, Tonekabon, Iran
2 Blood Borne Infections Research Center, Academic Center for Education, Culture and Research (ACECR), Razavi Khorasan Branch, Mashhad, Iran
3 Medical Diagnostic Laboratory of Neyshabour, Center of Medical, Pathological and Genetic Diagnostic Services, Iranian Academic Center for Education, Culture and Research (ACECR), Mashhad Branch, Mashhad, IR Iran
Article information
  • Archives of Pediatric Infectious Diseases: October 2017, 5 (4); e61654
  • Published Online: October 2, 2017
  • Article Type: Research Article
  • Received: July 26, 2016
  • Revised: January 5, 2016
  • Accepted: November 8, 2016
  • DOI: 10.5812/pedinfect.61654

To Cite: Asghar Heydari M, Mobini M, Salehi M. The Synergic Activity of Eucalyptus Leaf Oil and Silver Nanoparticles Against Some Pathogenic Bacteria, Arch Pediatr Infect Dis. 2017 ; 5(4):e61654. doi: 10.5812/pedinfect.61654.

Copyright © 2017, Archives of Pediatric Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Powers JH. Antimicrobial drug development--the past, the present, and the future. Clin Microbiol Infect. 2004; 10 Suppl 4: 23-31[DOI][PubMed]
  • 2. Rizzello L, Pompa PP. Nanosilver-based antibacterial drugs and devices: mechanisms, methodological drawbacks, and guidelines. Chem Soc Rev. 2014; 43(5): 1501-18[DOI][PubMed]
  • 3. Spellberg B. Dr. William H. Stewart: mistaken or maligned? Clin Infect Dis. 2008; 47(2): 294[DOI][PubMed]
  • 4. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46(2): 155-64[DOI][PubMed]
  • 5. Fauci AS. Infectious diseases: considerations for the 21st century. Clin Infect Dis. 2001; 32(5): 675-85[DOI][PubMed]
  • 6. Fauci AS. Emerging and reemerging infectious diseases: the perpetual challenge. Acad Med. 2005; 80(12): 1079-85[PubMed]
  • 7. Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. Nature. 2004; 430(6996): 242-9[DOI][PubMed]
  • 8. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol. 2010; 8(4): 260-71[DOI][PubMed]
  • 9. Levin BR, Rozen DE. Non-inherited antibiotic resistance. Nat Rev Microbiol. 2006; 4(7): 556-62[DOI][PubMed]
  • 10. Schwaber MJ, De-Medina T, Carmeli Y. Epidemiological interpretation of antibiotic resistance studies - what are we missing? Nat Rev Microbiol. 2004; 2(12): 979-83[DOI][PubMed]
  • 11. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med. 2004; 10(12 Suppl)-9[DOI][PubMed]
  • 12. Boucher HW. Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication. Clin Infect Dis. 2010; 50 Suppl 1-9[DOI][PubMed]
  • 13. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48(1): 1-12[DOI][PubMed]
  • 14. Roberts L, Simpson S. Drug resistance. Deadly defiance. Introduction to special issue. Science. 2008; 321(5887): 355[DOI][PubMed]
  • 15. Kresse H, Belsey MJ, Rovini H. The antibacterial drugs market. Nat Rev Drug Discov. 2007; 6(1): 19-20[DOI][PubMed]
  • 16. Projan SJ, Shlaes DM. Antibacterial drug discovery: is it all downhill from here? Clin Microbiol Infect. 2004; 10 Suppl 4: 18-22[DOI][PubMed]
  • 17. Baker-Austin C, Wright MS, Stepanauskas R, McArthur JV. Co-selection of antibiotic and metal resistance. Trends Microbiol. 2006; 14(4): 176-82[DOI][PubMed]
  • 18. Whitesides GM. Nanoscience, nanotechnology, and chemistry. Small. 2005; 1(2): 172-9[DOI][PubMed]
  • 19. Marambio-Jones C, Hoek EMV. A review of the antibacterial effects of silver nanomaterials and potential implications for human health and the environment. J Nanoparticle Res. 2010; 12(5): 1531-51[DOI]
  • 20. Devi LS, Joshi SR. Antimicrobial and synergistic effects of silver nanoparticles synthesized using soil fungi of high altitudes of eastern himalaya. Mycobiology. 2012; 40(1): 27-34[DOI][PubMed]
  • 21. Scandorieiro S, de Camargo LC, Lancheros CA, Yamada-Ogatta SF, Nakamura CV, de Oliveira AG, et al. Synergistic and Additive Effect of Oregano Essential Oil and Biological Silver Nanoparticles against Multidrug-Resistant Bacterial Strains. Front Microbiol. 2016; 7: 760[DOI][PubMed]
  • 22. Delaquis PJ, Stanich K, Girard B, Mazza G. Antimicrobial activity of individual and mixed fractions of dill, cilantro, coriander and eucalyptus essential oils. Int J Food Microbiol. 2002; 74(1-2): 101-9[PubMed]
  • 23. Sartorelli P, Marquioreto AD, Amaral-Baroli A, Lima ME, Moreno PR. Chemical composition and antimicrobial activity of the essential oils from two species of Eucalyptus. Phytother Res. 2007; 21(3): 231-3[DOI][PubMed]
  • 24. O. Oyedeji A, Ekundayo O, Olawore ON, Adeniyi BA, Koenig WA. Antimicrobial activity of the essential oils of five Eucalyptus species growing in Nigeria. Fitoterapia. 1999; 70(5): 526-8[DOI]
  • 25. Hendry ER, Worthington T, Conway BR, Lambert PA. Antimicrobial efficacy of eucalyptus oil and 1,8-cineole alone and in combination with chlorhexidine digluconate against microorganisms grown in planktonic and biofilm cultures. J Antimicrob Chemother. 2009; 64(6): 1219-25[DOI][PubMed]
  • 26. Trivedi NA, Hotchandani SC. A study of the antimicrobial activity of oil of Eucalyptus. Indian J Pharmacol. 2004; 36(2): 93
  • 27. Performance standards for antimicrobial disk susceptibility test. Approved standard M02-A10. 2009;
  • 28. Methods for Dilution Antimicrobial Susceptibility Tests f or Bacteria That Grow Aerobically;Approved St andard-Ninth Edition. CLSI document M07-A9. 2012;
  • 29. Mirzaei F, Salouti M, Shapouri R, Heidari Z. Antimicrobial effect of plant peptide MBP-1 and silver nanoparticles, along with their synergistic effect on skin infection due to Pseudomonas aeruginosa: in vitro and animal model. Pajoohandeh J. 2013; 18(2): 64-8
  • 30. Sharifi-Rad J, Hoseini Alfatemi S, Sharifi Rad M, Iriti M. Antimicrobial Synergic Effect of Allicin and Silver Nanoparticles on Skin Infection Caused by Methicillin-Resistant Staphylococcus aureus spp. Ann Med Health Sci Res. 2014; 4(6): 863-8[DOI][PubMed]
  • 31. Naghsh N, Ghiasian M, Soleymani S, Torkan S. Investigation of Eucalyptus and nanosilver as a new nanomixture for growth inhibition of E. coli. Int J Mol Clin Microbiol. 2012; 2(1): 138-40
  • 32. Naghsh N, Ghyasiyan M, Soleimani S, Torkan S. Comparison between alcoholic eucalyptus and nano-silver as a new nanocomposition in growth inhibition of Aspergilus niger. Indian J Sci Technol. 2012; 5: 2445-7
  • 33. Leid JG, Ditto AJ, Knapp A, Shah PN, Wright BD, Blust R, et al. In vitro antimicrobial studies of silver carbene complexes: activity of free and nanoparticle carbene formulations against clinical isolates of pathogenic bacteria. J Antimicrob Chemother. 2012; 67(1): 138-48[DOI][PubMed]
  • 34. Sheikholeslami S, Mousavi SE, Ahmadi Ashtiani HR, Hosseini Doust SR, Mahdi Rezayat S. Antibacterial Activity of Silver Nanoparticles and Their Combination with Zataria multiflora Essential Oil and Methanol Extract. Jundishapur J Microbiol. 2016; 9(10)[DOI][PubMed]
  • 35. Narayanan KB, Sakthivel N. Green synthesis of biogenic metal nanoparticles by terrestrial and aquatic phototrophic and heterotrophic eukaryotes and biocompatible agents. Adv Colloid Interface Sci. 2011; 169(2): 59-79[DOI][PubMed]
  • 36. Martinez-Castanon GA, Nino-Martinez N, Martinez-Gutierrez F, Martinez-Mendoza JR, Ruiz F. Synthesis and antibacterial activity of silver nanoparticles with different sizes. J Nanoparticle Res. 2008; 10(8): 1343-8[DOI]
  • 37. Lara HH, Garza-Trevino EN, Ixtepan-Turrent L, Singh DK. Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds. J Nanobiotechnology. 2011; 9: 30[DOI][PubMed]
  • 38. Musee N, Thwala M, Nota N. The antibacterial effects of engineered nanomaterials: implications for wastewater treatment plants. J Environ Monit. 2011; 13(5): 1164-83[DOI][PubMed]
  • 39. Allahverdiyev AM, Abamor ES, Bagirova M, Rafailovich M. Antimicrobial effects of TiO(2) and Ag(2)O nanoparticles against drug-resistant bacteria and leishmania parasites. Future Microbiol. 2011; 6(8): 933-40[DOI][PubMed]
  • 40. Guzman M, Dille J, Godet S. Synthesis and antibacterial activity of silver nanoparticles against gram-positive and gram-negative bacteria. Nanomedicine. 2012; 8(1): 37-45[DOI][PubMed]
  • 41. Thill A, Zeyons O, Spalla O, Chauvat F, Rose J, Auffan M, et al. Cytotoxicity of CeO2 nanoparticles for Escherichia coli. Physico-chemical insight of the cytotoxicity mechanism. Environ Sci Technol. 2006; 40(19): 6151-6[PubMed]
  • 42. Soenen SJ, Rivera-Gil P, Montenegro JM, Parak WJ, De Smedt SC, Braeckmans K. Cellular toxicity of inorganic nanoparticles: Common aspects and guidelines for improved nanotoxicity evaluation. Nano Today. 2011; 6(5): 446-65[DOI]
  • 43. Nel AE, Madler L, Velegol D, Xia T, Hoek EM, Somasundaran P, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 2009; 8(7): 543-57[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments